Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients
Breast cancer (BC) categorized as human epidermal growth factor receptor 2 (HER2) borderline [2+ by immunohistochemistry (IHC 2+)] presents challenges for the testing, frequently obscured by intratumoral heterogeneity (ITH). This leads to difficulties in therapy decisions. We aimed to establish prog...
Guardado en:
Autores principales: | Gedmante Radziuviene, Allan Rasmusson, Renaldas Augulis, Ruta Barbora Grineviciute, Dovile Zilenaite, Aida Laurinaviciene, Valerijus Ostapenko, Arvydas Laurinavicius |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/73d1a54944394a3f9f244347fdfc92a2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tumor collagen framework from bright-field histology images predicts overall survival of breast carcinoma patients
por: Mindaugas Morkunas, et al.
Publicado: (2021) -
Intranuclear birefringent inclusions in paraffin sections by polychromatic polarization microscopy
por: Aiste Vitkunaite, et al.
Publicado: (2021) -
Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities
por: Sharanya Maanasi Kalasekar, et al.
Publicado: (2021) -
Advances in Injectable In Situ-Forming Hydrogels for Intratumoral Treatment
por: Gi Ru Shin, et al.
Publicado: (2021) -
Tumor Heterogeneity and Consequences for Bladder Cancer Treatment
por: Etienne Lavallee, et al.
Publicado: (2021)